GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vor Biopharma Inc (NAS:VOR) » Definitions » Beta

Vor Biopharma (Vor Biopharma) Beta : -0.38 (As of Apr. 28, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Vor Biopharma Beta?

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2024-04-28), Vor Biopharma's Beta is -0.38.


Vor Biopharma Beta Historical Data

The historical data trend for Vor Biopharma's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vor Biopharma Beta Chart

Vor Biopharma Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beta
Get a 7-Day Free Trial - - - - -

Vor Biopharma Quarterly Data
Dec18 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Vor Biopharma's Beta

For the Biotechnology subindustry, Vor Biopharma's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vor Biopharma's Beta Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vor Biopharma's Beta distribution charts can be found below:

* The bar in red indicates where Vor Biopharma's Beta falls into.



Vor Biopharma Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.


Vor Biopharma  (NAS:VOR) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Vor Biopharma Beta Related Terms

Thank you for viewing the detailed overview of Vor Biopharma's Beta provided by GuruFocus.com. Please click on the following links to see related term pages.


Vor Biopharma (Vor Biopharma) Business Description

Traded in Other Exchanges
N/A
Address
100 Cambridgepark Drive, Suite 101, Cambridge, MA, USA, 02140
Vor Biopharma Inc is a clinical stage cell therapy company. It combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies. The company's products include VOR33.
Executives
Eyal C. Attar officer: Chief Medical Officer 535 BOYLSTON STREET, BOSTON MA 02116
5am Ventures Vi, L.p. 10 percent owner 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
Kush Parmar director, 10 percent owner C/O 5AM VENTURES, 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
Ra Capital Healthcare Fund Lp director, 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Nathan D. Jorgensen officer: Chief Financial Officer C/O VOR BIOPHARMA INC., 100 CAMBRIDGEPARK DRIVE, SUITE 400, CAMBRIDGE MA 02140
Christopher Slapak officer: Chief Medical Officer C/O VOR BIOPHARMA INC., 100 CAMBRIDGEPARK DRIVE, SUITE 400, CAMBRIDGE MA 02140
Sadik Kassim officer: Chief Technology Officer C/O VOR BIOPHARMA INC., 100 CAMBRIDGEPARK DRIVE, SUITE 400, CAMBRIDGE MA 02140
Tirtha Chakraborty officer: Chief Scientific Officer C/O VOR BIOPHARMA INC., 100 CAMBRIDGEPARK DRIVE, SUITE 400, CAMBRIDGE MA 02140
Robert Ang director, officer: President and CEO C/O NEON THERAPEUTICS, 40 ERIE STREET, SUITE 110, CAMBRIDGE MA 02139
5am Partners Vi, Llc 10 percent owner 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
David Charles Lubner director C/O TETRAPHASE PHARMACEUTICALS, INC., 480 ARSENAL STREET, SUITE 110, WATERTOWN MA 02472
Puretech Health Llc 10 percent owner 501 BOYLSTON STREET, SUITE 6102, BOSTON MA 02116
Daniella Beckman director C/O IDENIX PHARMACEUTICALS, INC., ONE KENDALL SQUARE, BLDG. 1400, CAMBRIDGE MA 02139
5am Opportunities I (gp), Llc 10 percent owner 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
5am Opportunities I, L.p. 10 percent owner 501 SECOND STREET, SUITE 350, SAN FRANCISCO CA 94107